Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer

Hee Seung Lee, Eunyoung Kim, Jinyoung Lee, Seung Joon Park, Ho Kyoung Hwang, Chan Hee Park, Se Young Jo, Chang Moo Kang, Seung Mo Hong, Huapyong Kang, Jung Hyun Jo, In Rae Cho, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Jung Min Han, Sangwoo Kim, Seungmin Bang

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The establishment of patient-derived models for pancreatic ductal adenocarcinoma (PDAC) using conventional methods has been fraught with low success rate, mainly because of the small number of tumour cells and dense fibrotic stroma. Here, we sought to establish patient-derived model of PDAC and perform genetic analysis with responses to anticancer drug by using the conditionally reprogrammed cell (CRC) methodology. Methods: We performed in vitro and in vivo tumourigenicity assays and analysed histological characteristics by immunostaining. We investigated genetic profiles including mutation patterns and copy number variations using targeted deep sequencing and copy-number analyses. We assessed the responses of cultured CRCs to the available clinical anticancer drugs based on patient responsiveness. Findings: We established a total of 28 CRCs from patients. Of the 28 samples, 27 showed KRAS mutations in codon 12/13 or codon 61. We found that somatic mutations were shared in the primary-CRC pairs and shared mutations included key oncogenic mutations such as KRAS (9 pairs), TP53 (8 pairs), and SMAD4 (3 pairs). Overall, CRCs preserved the genetic characteristics of primary tumours with high concordance, with additional confirmation of low-AF NPM1 mutation in CRC (35 shared mutations out of 36 total, concordance rate=97.2%). CRCs of the responder group were more sensitive to anticancer agents than those of the non-responder group (P < 0.001). Interpretation: These results show that a pancreatic cancer cell line model can be efficiently established using the CRC methodology, to better support a personalized therapeutic approach for pancreatic cancer patients. Funding: 2014R1A1A1006272, HI19C0642-060019, 2019R1A2C2008050, 2020R1A2C209958611, and 2020M3E5E204028211

Original languageEnglish
Article number103218
JournalEBioMedicine
Volume65
DOIs
Publication statusPublished - 2021 Mar

Bibliographical note

Funding Information:
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (Grant No.: 2014R1A1A1006272). This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI19C0642-060019). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2019R1A2C2008050). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (2020R1A2C209958611 and 2020M3E5E204028211). The funders did not have any role in the study design, data acquisition, analysis, interpretation, writing, or submission of the manuscript.

Funding Information:
The authors sincerely appreciate all patients who consented to participate in this study. The authors are deeply grateful to Dong-Su Jang, MFA, (Medical Illustrator, Medical Research Support Section, Yonsei University College of Medicine, Seoul, Korea) for his medical illustrations.

Publisher Copyright:
© 2021 The Authors

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer'. Together they form a unique fingerprint.

Cite this